Skip to main content

Table 1 Patient characteristics

From: The impact of chemotherapy-associated neutrophil/ lymphocyte counts on prognosis of adjuvant chemotherapy in colorectal cancer

Variables Number of cases Percentage(%)
Follow-up(months)   
Median(range) 31(7–103)  
Age(years)   
Median(range) 59(22–82)  
Pretreatment albumin   
≥35 g/L 173 71.2
<35 g/L 70 28.8
Pretreatment CEA a   
≤10 ng/ml 186 76.5
>10 ng/ml 57 23.5
Differentiation   
High 24 9.9
Middle 198 81.5
Low 21 8.6
Sex   
Male 134 55.1
Female 109 44.9
Age   
≤49 years 56 23.0
50-60 yeas 72 29.6
>60 years 115 47.3
am   
Rectum 111 45.7
Left colon cancer 77 31.7
Right colon cancer 55 22.6
Stage   
II 140 57.6
III 103 42.4
Baseline neutrophil counts(×10 9 /L)   
Mean(± SD) 4.27 ± 1.49  
Baseline lymphocyte counts(×10 9 /L)   
Mean(± SD) 1.88 ± 0.59  
Chemotherapy-associated neutrophil counts   
Neutrophil counts ≥ 1.5 × 109/L 153 63.0
Neutropenia < 1.5 × 109/L 90 37.0
Chemotherapy-associated lymphocyte counts   
Lymphocyte counts ≥ 1.0 × 109/L 139 57.2
Lymphopenia < 1.0 × 109/L 104 42.8
  1. a Carcinoembryonic antigen.